Summary: Leiomyoma with bizarre nuclei (LM-BN), is a variant of uterine smooth muscle tumor with atypical histologic features. Although some LM-BN share several significant genetic alterations with leiomyosarcoma, including p16 and p53, the underlying tumorigenesis of LM-BN remains largely unknown. As we previously reported, LM-BN can be divided into 2 subtypes, type I and type II, based on different nuclear features. Type I LM-BN have similar histologic features as uterine smooth muscle tumors with fumarate hydratase (FH) alterations. In this study, we examined FH expression and FH mutations in 77 LM-BN (40 type I cases and 37 type II cases). FH expression was examined by immunohistochemistry using S-(2-succino)-cysteine antibodies (2SC, a protein modification associated with FH inactivation and subsequent fumarate accumulation) and FH antibodies (FH gene products). Seventy-two LM-BN tumors underwent Sanger sequencing to detect FH mutations. We found that 51% (39/77) of LM-BN showed FH alterations detected by immunohistochemistry with both 2SC and FH. Mutational analysis showed that 21% (15/72) of LM-BN harbored FH gene mutations. Further analysis revealed that 85% (34/40) of those with FH alterations were type I LM-BN while 19% (7/37) were type II LM-BN. Our findings suggest that over half of histologically diagnosed LM-BN may be related to FH alterations or FH mutations and the majority of these have the characteristic histologic features of type I LM-BN.
Uterine smooth muscle tumors consist of a diverse group of tumors based on histologic features and clinical behavior. Currently the 2014 WHO classifies them as benign [including usual-type leiomyoma (ULM), leiomyoma with bizarre nuclei, cellular leiomyoma, mitotically active leiomyoma, and other rare variants], intermediate grade (atypical smooth muscle tumors) and malignant (leiomyosarcoma, LMS). Leiomyoma with bizarre nuclei (LM-BN) was changed from atypical leiomyoma due to its overall benign clinical course (1) (2) (3) (4) . Thus, we use the terminology LM-BN in this report based on the WHO recommendation. The biologic nature of LM-BN and its histologic relationship to benign (ULM), intermediate (atypical uterine smooth tumors) and malignant (LMS) uterine smooth muscle tumors remain unclear. Recently, several independent studies have investigated the molecular relationship among these variants and the results have shown that many cell cycle regulatory proteins including p16, p21, p27, and p53 are dysregulated in both LM-BN and LMS (2, (4) (5) (6) . Given the completely different clinical outcomes of these 2 entities, further investigation into LM-BN may assist in better understanding this tumor.
Fumarate hydratase (FH) mutations are most notably seen in hereditary leiomyomatosis and renal cell carcinoma syndrome, also known as Reed syndrome, and they can also be seen with uterine leiomyomatosis (7) . Somatic FH mutations have occasionally been identified in some patients treated for uterine leiomyomas (8) with a higher incidence seen in younger patients (9) . Further histologic analysis has revealed that some ULM with FH mutations have different nuclear and histologic features and can be referred to as smooth tumors with features of fumarate hydratase alteration (SMT-FH) (9, 10) . Historically, many sporadic SMT-FH were diagnosed as LM-BN due to the significant nuclear atypia (11, 12) . LM-BN also present with a wide range of histologic features (1, 3, 4) and in our set of tumors originally diagnosed as LM-BN, nearly half showed nuclear features similar to SMT-FH (9,10) and we therefore defined them as type I LM-BN (13) . This suggests that many uterine smooth muscle tumors with atypical histology diagnosed as LM-BN may be related to FH alterations/mutations.
In this study, we analyzed FH alterations/mutations in 77 cases of LM-BN. FH mutations were first examined by immunohistochemistry (IHC) using S-(2-succino)-cysteine antibodies (2SC), a substrate of FH that accumulates following inactivation of FH, and then by FH antibody to identify the fumarate hydratase gene products. The FH gene was then sequenced for each tumor. Both IHC and molecular sequencing identified distinct patterns of FH alterations in the 2 LM-BN subtypes.
MATERIALS AND METHODS

Case Selection
This study was approved by the Northwestern University Institutional Review Board (IRB). A total of 77 cases of LM-BN were retrieved from the pathology databases at Northwestern Memorial Hospital (Northwestern University, Chicago, IL) and Qilu Hospital (Shandong University, Shandong, China). This included 49 cases from Northwestern Memorial Hospital and 28 cases from Qilu Hospital. The slides from each case were reviewed by 2 pathologists to confirm the original diagnosis using the Bell et al (14) criteria and clinical information from each patient's chart was also recorded. Detailed case information is summarized in Table 1 .
Histologic Features of Type I and II LM-BN
By reviewing all tumor slides, LM-BN were divided into 2 subtypes purely based on distinct nuclear features. Type I LM-BN were characterized by large round or oval nuclei, distinct smooth nuclear membranes, prominent nucleoli, and open chromatin (Fig. 1) . Type II LM-BN were characterized by elongated or spindled nuclei, irregular nuclear membranes, pinpoint or no nucleoli, and dark smudgy chromatin (Fig. 1) . For those cases with mixed type I and II nuclear features, we defined cases as either type I or II when over 70% of the tumor cells appeared to show nuclear features favoring one or another. The detailed description of type I and II characterization has been outlined in a previous study (13) .
Immunohistochemical Analysis
Antigen retrieval was performed by first microwaving in a citrate buffer at a pH 6.0 for 15 minutes then blocking for endogenous peroxidase. The specimen was then incubated with anti-2SC polyclonal antibody (1:5000) and washed in phosphate buffered saline. Myometrium was used as a negative control. The 2SC antibody (15) was provided by Dr Norma Frizzell and used as previously described (16) . FH from Santa Cruz Biotechnology was used at a dilution of 1:200 (J-13 fumarate hydratase, Santa Cruz Biotechnology, Santa Cruz, CA). The IHC stains were analyzed blindly by 2 pathologists and the percent staining and staining intensity (0 = negative, 1+ = weak, 2+ = moderate, and 3 + = strong) were recorded for each case. Strong and Semiquantitative scores for each tumor and matched myometrial controls were calculated using the staining intensity and percentage. We found that both 2SC and FH IHC had specific staining patterns and were easily identified by their positive or negative stain. 2SC positivity was defined as diffusely strong immunoreactivity for 2SC while weak or focal immunoreactivity for 2SC was considered negative. FH negativity was defined as complete absence of immunoreactivity for FH in tumor cells.
Molecular Analysis
Mutational analysis for FH was performed on 72 of the LM-BN cases. Pure tumor tissues were sectioned at 10 μm and genomic DNA was extracted from formalin-fixed and paraffin-embedded tissue using the QIAamp DNA FFPE Tissue Kit (QIA-GEN, 56404). For FH mutational analysis, 50 ng DNA was amplified by PCR with HotStarTaq Master Mix (QIAGEN, 203446) at all ten FH exons. PCR products were then purified using the Gel Extraction and PCR Clean-Up Kit (Clontech) according to the user's manual. DNA sequencing of the purified DNA products was performed using the ABI 3730 HighThroughput DNA Sequencer. The mutations and variations were analyzed using DNASTAR Lasergene 9 software. Detailed information regarding primers can be found in Supplementary Table 1 Statistical Analysis SPSS Version 19.0 was used for statistical analysis. The mean differences between clinical parameters and histologic features were analyzed using a student T test. Positivity rates for each gene were performed using the Pearson χ 2 test and the Fisher exact test. The association between 2SC and FH IHC expression was evaluated using the Pearson coefficient. P-values <0.05 were considered statistically significant.
RESULTS
General Case Information
We reviewed and confirmed the diagnosis for 77 LM-BN cases by Bell et al's (14) criteria. The patient age ranged from 21 to 65 yr with a median age of 40 yr and the mean tumor size was 7.7 cm (Table 1) . LM-BN were further divided into 2 categories, type I and type II, based on nuclear features (13) . Type I LM-BN showed round-to-oval nuclei, distinct and smooth nuclear membranes, prominent nucleoli with perinucleolar halos, and open chromatin (Fig. 1) . Type II LM-BN showed large elongated or spindled nuclei, irregular nuclear membranes, pinpoint or absent nucleoli, and dark smudgy chromatin (Fig. 1) . In general, type I LM-BN patients were younger (mean age of 38 yr) than that of type II (mean age of 43 yr, Po 0.01) and the mean overall tumor size was larger in type I than in type II (8.7 vs. 6.7 cm, Po 0.05) ( Table 1) . Seventy-two of the 77 patients had more than 1 uterine nodule. The additional nodules were either additional LM-BN or ULM. The general information is summarized in Table 1 . Immunohistochemical Analysis of 2SC 2SC is a downstream biomarker for biallelic FH inactivation and strong IHC reactivity has been shown to be a sensitive marker in detecting defective FH enzyme function in tumor cells (Fig. 2) . In the 77 LM-BN cases, diffuse positivity for 2SC was found in 53% (41/77) of cases while all 60 myometrial controls were completely negative (Fig. 2B) . Overall, patients with 2SC immunoreactivity were younger and had a larger tumor burden than the 2SC negative cases (Po0.05). In addition, histologic features including prominent nucleoli, perinucleolar halos, hyaline globules, and staghorn vessels had high concordance with 2SC IHC positivity ( Table 2) .
Next, immunoreactivity for 2SC was compared between type I and type II LM-BN. Of the 40 type I LM-BN cases, 85% (34/40) were 2SC positive (Fig. 2) , while 19% (7/37) of type II were positive for 2SC (Po0.01) ( Table 3 ). These findings suggest that the majority of type I LM-BN were related to FH alterations and only a small fraction of type I LM-BN (7/40) were completely negative for 2SC by IHC (Fig. 3) . As shown in Figure 3 , tumors with characteristic nuclear features of type I LM-BN that were completely negative for 2SC were rereviewed. To confirm that there were no misdiagnoses of uterine PEComa, immunohistochemical stains for Melanin A and HMB45 were performed and were negative for all cases. Of the 37 type II LM-BN, 81% (30/37) were negative for 2SC (Fig. 4) and only 19% were positive for 2SC by IHC (Fig. 5) . While the nuclear features of type I LM-BN strongly correlated with 2SC immunopositivity, this alone was not always an accurate predictor of 2SC positivity (Table 3 ). The positive rates of 2SC in LM-BN between the 2 different institutions were also similar (55% vs. 51%, respectively).
Immunohistochemical Analysis of FH
2SC immunoreactivity detects the byproduct of accumulated fumarate in tumors with defective FH. While it appears to be sensitive, its specificity for FH gene mutations in uterine smooth muscle tumors is still unclear (8, 10, 17) . Thus, to test this concept further to see whether 2SC-positive tumors are indeed caused by FH genetic alterations, all cases were also stained with FH antibodies. FH IHC should be negative in tumors with loss of FH and is quite specific (17) . As illustrated in Figure 2 , complete absence of the immunostain in tumor cells for FH was identified and compared to myometrial tissue and internal endothelial cells. Among the 41 cases of 2SC-positive LM-BN, 95% (39/41) were negative for FH by IHC (Fig. 2) . A Pearson rate correlating the 2SC and FH immunohistochemical staining was −0.939 (Table 4) . Only 2 cases were positive for both markers and FH mutational analysis revealed that neither of those cases had FH mutations (see below). All 36 2SC-negative cases were also FH-positive (Fig. 4) . Overall, IHC for 2SC and FH were complimentary to each other in almost all cases and can be reliably used to detect FH alterations in LM-BN (Figs. 2, 4 , Table 3 ).
Molecular Analysis
The immunohistochemical analysis of 2SC and FH appears to be both sensitive and specific in identifying FH alterations in LM-BN cells. To test whether the alterations of FH expression by IHC were due to FH gene mutations, FH gene mutation analysis was conducted in 72 LM-BN cases using Sanger sequencing, specifically looking at the 10 exons of the FH gene. Among the 72 LM-BN cases, 21% (15/72) harbored FH mutations. In our current study, 36.6% (15/41) of 2SC-positive LM-BN harbored FH gene mutations, mainly comprised of missense mutations (Fig. 5) . FH mutations were found in 38.5% (15/39) cases that were negative for FH by IHC. The FH mutant tumors were exclusively identified in tumors with positive 2SC and negative FH by IHC (Table 3 and Fig. 6 ). Yet, there was still a large number of 2SC-positive and FH-negative cases by IHC with no detectable FH mutations by sequencing analysis.
DISCUSSION
FH alterations are seen in hereditary leiomyomatosis and renal cell carcinoma syndrome (Reed Syndrome) and FH germline mutations are present in 85% of these cases (20) . In contrast, the incidence of FH mutations in sporadic leiomyoma is very low. Previous studies have shown only 1% of unselected leiomyomas will have FH-deficiency and most are somatically acquired FH mutations (Table 4) (8, 9, 18, 19) . In uterine leiomyomas from patients younger than 40 yr of age, FH mutations have been reported to be only slightly higher, accounting for 2.57% of these cases (9) . In addition, FH mutations in LMS have occasionally been reported (22, 23) . In those leiomyomas with FH gene mutations, some have characteristic histologic features, defined as SMT-FH (10,11) ( Table 4 ). These tumors are typically cellular with eosinophilic macronucleoli, perinucleolar halos, and eosinophilic cytoplasmic globules. They also frequently show branching staghorn vessels. Miettinen and colleagues examined FH IHC staining in different types of uterine smooth muscle tumors and found 37% of LM-BN were negative for FH by IHC (Table 4) . SC is another protein that may be used as a sensitive and specific marker for fumarate in the setting of defective FH and can be used as a surrogate marker for FH by IHC (10) . Absent immunohistochemical staining for FH has also been shown to have high specificity when evaluating FH alterations (8, 10, 24) . Using the 2 IHC stains in combination, along with FH mutational analysis, appears to be an extremely reliable way to confirm FH alterations and mutations in LM-BN. In our study, the 77 cases with an LM-BM diagnosis were divided into 2 subtypes based on cytologic features (13) , with type I LM-BN showing features similar to SMT-FH (Fig. 1) (13) . In total, there were 40 cases showing type I features and 37 with type II features. We found that 85% of type I LM-BN were strongly and diffusely immunoreactive for 2SC (Table 3 and Fig. 2 ) and all but 2 of those cases also showed loss of immunoreactivity for FH. These findings suggest that most, if not all, type I LM-BN are related to FH alterations. We found that roughly 20% of all LM-BN had FH mutations and 37% (15/41) of those with 2SC positivity by IHC harbored FH mutations ( Table 3) . The underlying molecular mechanisms for FH alterations in the remaining cases needs to be further investigated. Our findings suggest that for those sporadic tumors originally diagnosed as LM-BN, careful evaluation of their nuclear features may be helpful in the potential differential diagnosis of an FH-related tumor. All type I LM-BN tumors and tumors with SMT-FH features should be tested for FH alterations by 2SC/FH IHC or by mutational analysis. Recently Joseph et al. (9) proposed an algorithm for screening SMT-FH in young patients and we believe their approach should also be applied to all LM-BN cases. As nearly 20% of the type II LM-BN in our study presented with FH alterations by As summarized in Table 4 , the rate of FH mutations in hereditary leiomyomatosis and renal cell carcinoma syndrome is quite high (20) while the rate in sporadic LM-BN is largely unknown. The results from Miettinen et al. (21) concur with our current study, We have shown that FH alterations can be detected by IHC for 2SC and that FH mutations appear to be disproportionately higher in LM-BN than in other types of sporadic uterine smooth muscle tumors including ULM, although additional FH gene mutation analysis is still needed. Our current study reveals that over 20% (15/72) of LM-BN harbor FH mutations and over one-third with FH IHC alterations also have corresponding FH gene mutations (Fig. 6 ). The subset that shows FH alterations by IHC without an associated genetic cause requires further study. In a recent study, Liegl-Atzwanger et al. (25) reported that FH genomic deletions can be found in over 30% LM-BN.
Preliminary data from our cohort also showed that in 4 cases of LM-BN with extracted DNA failed to amplify in any of the 10 FH exons, suggestive of FH genomic deletions.
2SC is a sensitive and specific immunohistochemical marker for detection of FH deficiency, whereas negative staining for FH by IHC is more specific. We found a high concordance rate between these 2 markers in FH-altered tumors, with 39 of 41 2SC-positive cases also showing loss of FH by IHC (Table 4) . For those 2 cases with immunoreactivity for both 2SC and FH, we postulate that there are likely other molecular defects resulting in succinate accumulation in this small subset of LM-BN (∼5%). Yet FH by IHC alone is sensitive enough to detect over 95% of FH alterations and it can be used alone for routine screening.
The correlation of 2SC and FH by IHC and their concordance with FH gene mutations in uterine smooth muscle tumors is of great clinical interest. The most common type of mutations are missense mutations (57%), followed by frameshift and nonsense mutations (27%), with the remainder consisting of a diverse array of deletions, insertions, and duplications (26) . In our current study, 36.6% (15/41) of 2SC positive LM-BN harbored FH gene mutations and they were mainly missense mutations (Fig. 6) . As the FH gene is located in chromosome 1q and this region has been found to be deleted frequently in uterine smooth muscle tumors (27) (28) (29) , analysis of additional chromosomal alterations deserves further investigation.
This study examined FH alterations and mutations by IHC and gene mutation analysis in 77 LM-BN. More than 50% of cases originally diagnosed as LM-BN were related to FH alterations and over 20% of them harbored FH gene mutations. FH alterations and mutations were more frequently identified in type I LM-BN, suggesting a different mode of tumorigenesis in this histologic tumor subtype and which may have important clinical implications in this subset of patients.
